Table 1 Baseline characteristics of the patients enrolled in the ANRS 138 EASIER trial

Age (years)

 Median

47.6

48.4

 Interquartile range

43.0; 53.7

44.0; 54.3

Male sex, no. (%)

70 (83)

73 (86)

Route of HIV infection, no. (%)

 Sexual

73 (87)

74 (87)

 Injection-drug use

5 (6)

5 (6)

 Other or unknown

6 (7)

6 (7)

CDC stage, no. (%)

 A

16 (19)

14 (16)

 B

26 (31)

24 (28)

 C

42 (50)

47 (55)

History of viral hepatitis co-infection

 HBs Ag positive

1 (1)

0 (0)

 HCV RNA positive

6 (7)

4 (5)

Cirrhosis

0 (0)

0 (0)

Non alcoolic fatty liver disease

9 (11)

5 (6)

Alcohol consumption

 ≥3 times per week

11 (13)

19 (22)

ALAT levels at baseline

 Grade 0

75 (89)

76 (89)

 Grade 1

8 (10)

7 (8)

 Grade 2

0 (0)

1 (1)

 Grade 3

1 (1)

0 (0)

 Grade 4

0 (0)

0(0)

Body mass index (BMI)

 Median

22.3

22.6

 Interquartile range

19.9; 24.0

20.6; 24.8

Baseline CD4 cells per μL

 Median

410

374

 Interquartile range

259; 505

277; 535

Plasma HIV RNA < 50 cp/mL, no. (%)

71 (85)

75 (88)

Duration of prior antiretroviral therapy (years)

 Median

13.7

13.6

 Interquartile range

12.1; 15.0

11.7; 15.4

Duration of prior enfuvirtide therapy (years)

 Median

2.5

2.2

 Interquartile range

1.6; 3.5

1.4; 3.4

Number of antiretroviral drugs in baseline regimen (including enfuvirtide)

 Median

4

4

 Interquartile range

4; 5

4; 5

Antiretroviral drugs in baseline regimen (apart from enfuvirtide)

 Protease inhibitors, no. (%)

83 (99)

85 (100)

  Tipranavir/ritonavir

37 (44)

29 (34)

  Darunavir/ritonavir

30 (36)

34 (40)

  Atazanavir/ritonavir

2 (2)

2 (2)

  Lopinavir/ritonavir

9 (11)

15 (18)

  Fosamprenavir/ritonavir

11 (13)

11 (13)

 NRTIs, no. (%)

79 (94)

81 (95)

  Tenofovir

50 (60)

46 (54)

  Lamivudine

36 (43)

32 (38)

  Emtricitabine

26 (31)

28 (33)

  Abacavir

31 (37)

29 (34)

 NNRTIs, no. (%)

8 (10)

5 (6)

  Nevirapine

5 (6)

1 (1)

  Efavirenz

3 (4)

3 (4)

  Etravirine

0 (0)

1 (1)